JP2023076465A5 - - Google Patents

Download PDF

Info

Publication number
JP2023076465A5
JP2023076465A5 JP2023034704A JP2023034704A JP2023076465A5 JP 2023076465 A5 JP2023076465 A5 JP 2023076465A5 JP 2023034704 A JP2023034704 A JP 2023034704A JP 2023034704 A JP2023034704 A JP 2023034704A JP 2023076465 A5 JP2023076465 A5 JP 2023076465A5
Authority
JP
Japan
Prior art keywords
formulation
dexmedetomidine
minutes
subject
insomnia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023034704A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023076465A (ja
Filing date
Publication date
Priority claimed from JP2021025810A external-priority patent/JP2021080276A/ja
Application filed filed Critical
Publication of JP2023076465A publication Critical patent/JP2023076465A/ja
Publication of JP2023076465A5 publication Critical patent/JP2023076465A5/ja
Priority to JP2025030902A priority Critical patent/JP2025092508A/ja
Pending legal-status Critical Current

Links

JP2023034704A 2014-10-15 2023-03-07 デクスメデトミジン製剤を使用する睡眠障害の予防または治療 Pending JP2023076465A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025030902A JP2025092508A (ja) 2014-10-15 2025-02-28 デクスメデトミジン製剤を使用する睡眠障害の予防または治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462064205P 2014-10-15 2014-10-15
US62/064,205 2014-10-15
JP2021025810A JP2021080276A (ja) 2014-10-15 2021-02-22 デクスメデトミジン製剤を使用する睡眠障害の予防または治療

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021025810A Division JP2021080276A (ja) 2014-10-15 2021-02-22 デクスメデトミジン製剤を使用する睡眠障害の予防または治療

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025030902A Division JP2025092508A (ja) 2014-10-15 2025-02-28 デクスメデトミジン製剤を使用する睡眠障害の予防または治療

Publications (2)

Publication Number Publication Date
JP2023076465A JP2023076465A (ja) 2023-06-01
JP2023076465A5 true JP2023076465A5 (https=) 2024-03-25

Family

ID=55747372

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017520539A Pending JP2017534613A (ja) 2014-10-15 2015-10-15 デクスメデトミジン製剤を使用する睡眠障害の予防または治療
JP2021025810A Pending JP2021080276A (ja) 2014-10-15 2021-02-22 デクスメデトミジン製剤を使用する睡眠障害の予防または治療
JP2023034704A Pending JP2023076465A (ja) 2014-10-15 2023-03-07 デクスメデトミジン製剤を使用する睡眠障害の予防または治療
JP2025030902A Pending JP2025092508A (ja) 2014-10-15 2025-02-28 デクスメデトミジン製剤を使用する睡眠障害の予防または治療

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2017520539A Pending JP2017534613A (ja) 2014-10-15 2015-10-15 デクスメデトミジン製剤を使用する睡眠障害の予防または治療
JP2021025810A Pending JP2021080276A (ja) 2014-10-15 2021-02-22 デクスメデトミジン製剤を使用する睡眠障害の予防または治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025030902A Pending JP2025092508A (ja) 2014-10-15 2025-02-28 デクスメデトミジン製剤を使用する睡眠障害の予防または治療

Country Status (5)

Country Link
US (3) US20170239221A1 (https=)
EP (1) EP3206685B1 (https=)
JP (4) JP2017534613A (https=)
MA (1) MA41689A (https=)
WO (1) WO2016061413A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL267689B2 (en) 2016-12-31 2025-05-01 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
BR112020026672A2 (pt) 2018-06-27 2021-03-30 Bioxcel Therapeutics, Inc. Formulações de filme contendo dexmedetomidina e métodos para produzi-las
BR112022000992A2 (pt) 2019-07-19 2022-06-14 Arx Llc Regimes de tratamento de dexmedetomidina não sedantes
CN118948739A (zh) * 2020-06-08 2024-11-15 四川普锐特药业有限公司 右美托咪定滴鼻剂或鼻喷剂在助眠药物制备中的应用
AU2022236605A1 (en) 2021-03-19 2023-11-02 Orion Corporation Tasipimidine formulations and use thereof
CN115197149B (zh) * 2021-04-02 2023-09-22 四川大学华西医院 一种5-苄基咪唑类化合物及其制备方法和用途
KR20240027808A (ko) * 2021-08-23 2024-03-04 이창 휴먼웰 파마슈티칼 코포레이션, 리미티드 덱스메데토미딘 경피 조성물, 투피 패치 및 그 제조 방법과 응용
WO2024023261A1 (en) 2022-07-27 2024-02-01 Universität Zürich Dexmedetomidine for the treatment of sleep disorders
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
KR102853305B1 (ko) * 2023-05-25 2025-09-01 가톨릭대학교 산학협력단 상추 추출물 및 대추 추출물을 유효성분을 함유하는 불면증 해소용 구강 붕해 필름 조성물
CN117771220B (zh) * 2024-02-28 2024-05-28 山东第二医科大学 一种右美托咪定中药多糖口溶膜剂及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7632517B2 (en) * 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
WO2002089794A1 (en) * 2001-05-07 2002-11-14 Universite Catholique De Louvain Method for treating neuropathic pain and pharmaceutical preparation therefor
US20050222270A1 (en) * 2004-02-26 2005-10-06 Olney John W Prolonged administration of NMDA antagonist drug and safener drug to create improved stable neural homeostasis
JP2008514612A (ja) * 2004-09-23 2008-05-08 ミシャロウ、アレクサンダー 対抗適応を誘発することにより神経伝達物質系を調節する方法
US7378508B2 (en) * 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
US20090076156A1 (en) * 2005-07-18 2009-03-19 Masud Husain Use of a noradrenergic agonist, e.g. guanfacine, for the treatment of cognitive disorders
NZ570492A (en) * 2006-02-13 2011-08-26 Orient Pharma Samoa Co Ltd Combination of alpha-2 receptor agonist (clonidin) and an anti-muscarinic agent (oxybutynin) for the treatment of excess salivation or drooling
WO2008091588A1 (en) * 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
CA2687085A1 (en) * 2007-05-10 2008-11-20 Novadel Pharma Inc. Anti-insomnia compositions and methods
PE20091084A1 (es) * 2007-12-07 2009-07-23 Schering Plough Healthcare Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal
US20100196286A1 (en) * 2008-12-01 2010-08-05 Armer Thomas A Inhalation delivery methods and devices
SG175979A1 (en) * 2009-05-15 2011-12-29 Recro Pharma Inc Sublingual dexmedetomidine compositions and methods of use thereof
US20130072532A1 (en) * 2010-01-08 2013-03-21 Recro Pharma, Inc. Topical transdermal dexmedetomidine compositions and methods of use thereof
US8241661B1 (en) * 2011-06-24 2012-08-14 Fuisz Richard C Biocompatible film with variable cross-sectional properties
WO2013061161A2 (en) * 2011-10-28 2013-05-02 Green Bcn Consulting Services Sl New combination therapies for treating neurological disorders
WO2013090278A2 (en) * 2011-12-11 2013-06-20 Recro Pharma, Inc. Intranasal dexmedetomidine compositions and methods of use thereof
CA2924233C (en) * 2013-10-07 2018-10-23 Teikoku Pharma Usa, Inc. Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions

Similar Documents

Publication Publication Date Title
JP2023076465A5 (https=)
JP2025092508A5 (https=)
JP2023041862A5 (https=)
JP2006523216A5 (https=)
JP2009514874A5 (https=)
JP2024517738A5 (https=)
JP2023545372A5 (https=)
JP2019503365A5 (https=)
JP2017528507A5 (https=)
JP2022504181A5 (https=)
ATE350040T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
JP2023522010A5 (https=)
BR9814378A (pt) Forma de dosagem de liberação prolongada farmacêutica revestida entérica de um inibidor de h+, k+-atpase, processos para a manufatura da mesma, para melhorar a inibição de secreção de ácido gástrico, para melhorar o efeito terapêutico no tratamento de distúrbios gastrointentinais, para receber um perfil de plasma prolongado de um inibidor da h+, k+-atpase, e, usos de uma composição farmacêutica e de inibidor da h+, k+-atpase
JP2014518252A5 (https=)
JP2017535613A5 (https=)
JP2007533687A5 (https=)
JP2026035701A5 (https=)
JP2022516662A5 (https=)
Aufdemorte et al. Griseofulvin in the treatment of three cases of oral erosive lichen planus
JP2021529829A5 (https=)
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
RS51452B (sr) Orodisperzivne farmaceutske smeše za oralnu, oromukozalnu ili sublingvalnu primenu agomelatina
JP2008542299A5 (https=)
MX2024006271A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
JP2020529995A5 (https=)